ECTRIMS2018

#ECTRIMS2018 – Ocrevus Used Early in MS Course Key to Slowing Disability, Genentech Director Says

Treating patients withĀ primary progressive or relapsing multiple sclerosis (MS) early with Ocrevus (ocrelizumab) is key to slowing disease progression, according to Hideki Garren, global head of Multiple Sclerosis and Neuroimmunology at Genentech. In an interview withĀ Multiple Sclerosis NewsĀ TodayĀ at the recentĀ 34thĀ congress of the European Committee for Treatment…

#ECTRIMS2018 – Finding Best Treatment for ‘Right Patient’ and Progressive MS Among Work of Interest, Cleveland Clinic Doctors Say

Tailored, highly effective therapies early in the disease’s course may be a way forward in multiple sclerosis (MS)Ā treatment, according to Cleveland Clinic neurologist Robert Bermel. Another neurologist with the Cleveland Clinic,Ā Robert Fox, talked about potential and upcoming progressive MS treatments.Ā  In interviews with Multiple Sclerosis News…

#ECTRIMS2018 – GNbAC1 Shows Consistent Neuroprotection in RRMS Patients, Phase 2b Study Reports

TreatingĀ relapsing-remitting multiple sclerosis (RRMS) patients with GeNeuroā€™s investigational compound GNbAC1 lessened brain atrophy and lesion load and suggested myelin preservation, according to results of a Phase 2b study. Importantly, monthly intravenous GNbAC1 administration for 48 weeks also had neuroprotective effects in the studyā€™s inactive population, which refers…

#ECTRIMS2018 – Two European Studies Compare Tecfidera, Aubagio Effectiveness

Treatment of relapsing-remitting multiple sclerosis (RRMS) patients with Tecfidera (dimethyl fumarate)Ā is associated with fewer new brain lesions at two years, lower relapse rates, increased time to first relapse, and reduced treatment discontinuation than with Aubagio (teriflunomide), according to a nationwide study from France and a real-world, population-based…

#ECTRIMS2018 – Plasma Neurofilament Light Levels Linked to Treatment Effects in RRMS, Study Finds

Levels of proposed biomarker neurofilament light chain (NfL) are associated with therapeutic effects of disease-modifying treatments (DMTs) inĀ relapsing-remitting multiple sclerosisĀ (RRMS) patients, according to a real-world study. Study findings also revealed that treatment with either Lemtrada (alemtuzumab, marketed byĀ Sanofi Genzyme),Ā Gilenya (fingolimod, marketed by Novartis), Tecfidera (dimethyl fumarate, marketed…

#ECTRIMS2018 ā€” Infections, Severe Disability Complications More Likely Causes of Death in MS Patients, Study Shows

Infections and complications from severe disability are the greatest contributors to mortality amongĀ multiple sclerosis (MS) patients, according to a population-based study in British Columbia, Canada, which also found that that MS is a more common underlying cause of death among younger patients. The study, ā€œCauses that…